Landscape Capital Management L.L.C. purchased a new position in Trupanion, Inc. (NASDAQ:TRUP – Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 103,455 shares of the financial services provider’s stock, valued at approximately $2,563,000.
Other institutional investors also recently bought and sold shares of the company. Kelleher Financial Advisors acquired a new stake in Trupanion during the 2nd quarter valued at approximately $42,000. Parallel Advisors LLC increased its stake in shares of Trupanion by 1,831.9% in the first quarter. Parallel Advisors LLC now owns 1,816 shares of the financial services provider’s stock worth $47,000 after acquiring an additional 1,722 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Trupanion in the fourth quarter worth $64,000. Advisory Services Network LLC purchased a new position in shares of Trupanion during the third quarter worth $160,000. Finally, Fifth Third Bancorp raised its holdings in shares of Trupanion by 2,911.1% during the first quarter. Fifth Third Bancorp now owns 7,588 shares of the financial services provider’s stock worth $194,000 after purchasing an additional 7,336 shares during the last quarter.
Trupanion Stock Performance
TRUP opened at $31.10 on Friday. The firm has a fifty day moving average price of $26.32 and a 200 day moving average price of $26.06. Trupanion, Inc. has a 1 year low of $21.16 and a 1 year high of $48.48. The stock has a market cap of $1.36 billion, a P/E ratio of 58.68, a P/E/G ratio of 2.10 and a beta of 1.39. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.77 and a quick ratio of 1.77.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on TRUP shares. Atlantic Securities set a $42.00 price target on shares of Trupanion in a report on Wednesday, July 15th. Weiss Ratings upgraded Trupanion from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. Zacks Research upgraded Trupanion from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Finally, Stifel Nicolaus raised their target price on Trupanion from $28.00 to $29.00 and gave the stock a “hold” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.80.
Check Out Our Latest Analysis on TRUP
Insiders Place Their Bets
In related news, CFO Fawwad Qureshi sold 6,177 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $22.18, for a total value of $137,005.86. Following the completion of the transaction, the chief financial officer owned 2,081 shares of the company’s stock, valued at approximately $46,156.58. This represents a 74.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Margaret Tooth sold 978 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $29.05, for a total value of $28,410.90. Following the transaction, the chief executive officer owned 175,401 shares in the company, valued at $5,095,399.05. This represents a 0.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,785 shares of company stock worth $422,862 in the last 90 days. 5.58% of the stock is currently owned by company insiders.
About Trupanion
Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company’s core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.
Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.
See Also
- Five stocks we like better than Trupanion
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding TRUP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trupanion, Inc. (NASDAQ:TRUP – Free Report).
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.
